Superworth

UroGen Pharma price to book ratio URGN

Market value divided by the book value of the company's net assets, since 2019.

Today, Oct 23, 2026
n/m
not a meaningful number
Last meaningful
16.2×
Mar 2025
8-year median
4.4×
8-year range
1.6× to 23.5×
Peer median
2.8×

UroGen Pharma's price to book ratio is not a meaningful number today: shareholders' equity was zero, negative or not reported, so price to book does not exist.

It was last meaningful in Mar 2025, at 16.2×.

On the days it had one over the last 8 years, its median was 4.4×, from 1.6× in Mar 2020 to 23.5× in Apr 2022.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
202516.2×15.6×18.5×
202417.8×16.8×21.0×
2023n/m a value too high to mean anything
202216.7×4.3×23.5×
20216.8×3.5×8.6×
20203.3×1.6×4.3×
20193.3×2.0×9.2×

Against its peers

Companies in Drug Manufacturers - General nearest UroGen Pharma's size, closest first, today.

CompanyPrice to book ratio
URGNUroGen Pharman/m
ANIPANI Pharmaceuticals2.8×
PAHCPhibro Animal Health4.1×
ANABAnaptysbio138×
PCRXPacira BioSciences2.2×
HRMYHarmony Biosciences2.1×
PBHPrestige Consumer Healthcare1.2×
OMEROmerosn/m
AMPHAmphastar Pharmaceuticals1.4×
NRIXNurix Therapeutics2.9×
ABUSArbutus Biopharma3.2×
Peer median2.8×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on UroGen Pharma

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.